The UK’s swift authorisation of Biontech and Pfizer’s Covid-19 shot has attracted both praise and concern.
mRNA-1273 shows 94.1% efficacy at its final analysis, in line with Pfizer/Biontech’s 95%.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
The first pivotal results with Moderna’s mRNA-based Covid-19 vaccine look even better than those Biontech/Pfizer released a week ago.
With more than 90% efficacy it seems clear that the partners’ Covid-19 vaccine works, but this is only the first hurdle.
Moderna battles Pfizer/Biontech to generate the first pivotal study data for a Covid-19 vaccine.
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.